journal article·2019-12-04Open access

Development and characterization of a novel cationic PEGylated niosome-encapsulated forms of doxorubicin, quercetin and siRNA for the treatment of cancer by using combination therapy

Mahdie Hemati, Fateme Haghiralsadat, Fatemeh Yazdian, Farzaneh Jafari, Ali Moradi, Zahra Malekpour-Dehkordi

Abstract

The aim of this study was to optimize the cationic PEGylated niosome-containing anti-cancer drugs and siRNA to enhance the therapeutic response. Therefore, various surfactant-based (tween-60) vesicles of doxorubicin (DOX; a chemotherapeutic drug) and quercetin (QC; a chemosensitizer) were prepared. To load siRNA on niosomes, 1, 2-dioleoyl-3-trimethylammonium-propane (DOTAP) was used as a cationic lipid. The optimum formulation containing tween-60:cholesterol:DPPC:DOTAP:DSPE-PEG2000 at 49.5:5.5:15:25:5 demonstrated that the vesicle size and zeta potential were 52.8 ± 2.7 nm and +27.4 ± 2.3 mV, respectively. Entrapment efficiency (EE%) for DOX and QC was 86.4 ± 2.1% and 94.9 ± 3.9%, respectively. Moreover, the drug release during 6 h was 32.1 ± 1.6% and 30.5 ± 1.3% for DOX and QC, respectively denoted on the controlled release. The gel retardation assay demonstrated that siRNA could be successfully loaded into a cationic niosome:siRNA in a weight ratio 40:1. Additionally, noisome-encapsulated drugs had a higher toxicity against cancer cells when compared with un-encapsulated forms and the synergistic effects of co-delivery of siRNA and DOX with QC on gastric, prostate, breast cancer cells as well as human foreskin fibroblast as a normal cell line was shown. The results showed that the co-delivery of drugs and siRNA using cationic PEGylated niosomes exhibited an increased anti-cancer activity against the tumor cell death. It seems that cationic PEGylated niosomes have opened up a new avenue to enrich the armamentarium of therapeutic agents to fight cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advancements in Transdermal Drug Delivery · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Clinical Biochemistry, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences

Department of Advanced Medical Sciences and Technologies, School of Paramedicine, Shahid Sadoughi University of Medical Sciences

Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran

Funding

Yazd University of Medical Sciences

References (38)

Show source-provided references
1. Saadat S, Yousefifard M, Asady H, et al. The most important causes of death in Iranian population; a retrospective cohort study. Emergency. 2015;3:16–21.
2. 10.1186/s13073-016-0379-810.1186/s13073-016-0379-8 ↗
3. 10.1016/j.jconrel.2014.09.00110.1016/j.jconrel.2014.09.001 ↗
4. 10.1021/acsami.6b0860310.1021/acsami.6b08603 ↗
5. 10.1080/1061186090304662810.1080/10611860903046628 ↗
6. 10.1002/jcp.2502610.1002/jcp.25026 ↗
7. 10.1038/srep2404910.1038/srep24049 ↗
8. 10.1111/bph.1279510.1111/bph.12795 ↗
9. Pappou EP, Ahuja N. The Role of oncogenes in gastrointestinal cancer. J Gastrointest Dig Syst. 2013(Suppl 1):S2–S15.
10. 10.1128/mcb.14.5.3350-3363.199410.1128/mcb.14.5.3350-3363.1994 ↗
11. 10.1158/1078-0432.CCR-11-8-COR-a10.1158/1078-0432.CCR-11-8-COR-a ↗
12. Ding ZY, Wu HR, Zhang JM, et al. Expression characteristics of CDC20 in gastric cancer and its correlation with poor prognosis. Int J Clin Exp Pathol. 2014;7:722–727.
13. 10.1038/mt.2011.29410.1038/mt.2011.294 ↗
14. 10.1038/nrd274210.1038/nrd2742 ↗
15. 10.1080/21691401.2017.139231610.1080/21691401.2017.1392316 ↗
16. 10.1080/21691401.2017.130440310.1080/21691401.2017.1304403 ↗
17. 10.1016/j.ijpharm.2008.05.03110.1016/j.ijpharm.2008.05.031 ↗
18. 10.1016/j.ijpharm.2011.11.03210.1016/j.ijpharm.2011.11.032 ↗
19. 10.1208/s12249-010-9480-210.1208/s12249-010-9480-2 ↗
20. 10.2147/IJN.S8470310.2147/IJN.S84703 ↗
21. 10.1016/j.ijpharm.2005.11.00610.1016/j.ijpharm.2005.11.006 ↗
22. 10.1016/0014-5793(90)81487-910.1016/0014-5793(90)81487-9 ↗
23. 10.1016/j.bbamem.2013.08.01410.1016/j.bbamem.2013.08.014 ↗
24. 10.1016/j.ajps.2014.09.00410.1016/j.ajps.2014.09.004 ↗
25. 10.1016/S0168-3659(01)00218-810.1016/S0168-3659(01)00218-8 ↗
26. 10.1016/j.biomaterials.2009.07.02110.1016/j.biomaterials.2009.07.021 ↗
27. 10.1517/14712598.8.8.106310.1517/14712598.8.8.1063 ↗
28. 10.1517/17425247.2012.67992610.1517/17425247.2012.679926 ↗
29. 10.1007/s13346-013-0176-510.1007/s13346-013-0176-5 ↗
30. 10.1002/jps.2002410.1002/jps.20024 ↗
31. 10.1098/rstb.2013.009910.1098/rstb.2013.0099 ↗
32. 10.1023/A:102013222611310.1023/A:1020132226113 ↗
33. 10.1039/C7RA01736G10.1039/C7RA01736G ↗
34. 10.3109/02652048.2013.78808810.3109/02652048.2013.788088 ↗
35. 10.1016/j.colsurfb.2013.09.05810.1016/j.colsurfb.2013.09.058 ↗
36. 10.1158/0008-5472.CAN-09-194710.1158/0008-5472.CAN-09-1947 ↗
37. 10.1371/journal.pone.010031410.1371/journal.pone.0100314 ↗
38. Samuel T, Fadlalla K, Mosley L, et al. Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells. Anticancer Res. 2012;32:61–71.